SANTA CLARA, CA / ACCESSWIRE / November 24, 2020 / SPI Energy Co., Ltd., (NASDAQ:SPI) (the "Company"), a global renewable energy company and provider of photovoltaic (PV) and electric vehicle (EV) solutions for business, residential, government, logistics and utility customers and investors, today announced that Wenbing Chris Wang was appointed Senior Vice President of Finance for the Company.

"Chris is a great addition to our team and will provide valuable support to our EdisonFuture's latest acquisition, Phoenix Motorcars, as well during our planned spinoff and IPO of our Solar Juice subsidiary," said Xiaofeng Peng, Chairman and CEO of SPI Energy.

Mr. Wang has been CEO of Redwood Group International since February 2017 and senior partner of SAIF Xinhuihuang Asset Management Co., Ltd since December 2018. Mr. Wang previously served as the President of Fushi Copperweld, Inc from 2009 to 2016 and the CFO of Fushi Copperweld from 2005 to 2010. Prior to that, Mr. Wang worked for Cornerstone China Opportunities Fund, Redwood Capital, Credit Suisse and VCChina in various capacities. Mr. Wang holds a bachelor's degree in English from the University of Science and Technology Beijing and an MBA degree in Finance and Corporate Accounting from University of Rochester.

"I am excited to join the SPI executive team as the Company moves to rapidly capitalize on the high-growth opportunities within the EV market globally," commented Mr. Wang.

About SPI Energy
SPI Energy Co., Ltd. (SPI) is a global renewable energy company and provider of photovoltaic (PV) and electric vehicle (EV) solutions for business, residential, government, logistics and utility customers and investors. The Company provides a full spectrum of EPC services to third party project developers, as well as develops, owns and operates solar projects that sell electricity to the grid in multiple countries, including the U.S., the U.K., Greece, Japan and Italy. The Company has its US headquarters in Santa Clara, California and maintains global operations in Asia, Europe, North America and Australia. SPI is also targeting strategic investment opportunities in green industries such as battery storage and charging stations, leveraging the Company's expertise and growing base of cash flow from solar projects and funding development of projects in agriculture and other markets with significant growth potential.

For more information on SPI Energy and its subsidiaries, the Company recommends that stockholders, investors and any other interested parties read the Company's public filings and press releases available under the Investor Relations section at www.SPIgroups.com or available at www.sec.gov.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company's current expectations and speak only as of the date of this release. Actual results may differ materially from the Company's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of the Company's annual report filed on Form 20-F filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to revise or update any forward-looking statements.

Contact:
SPI Energy Co., Ltd.
IR Department
Email: ir@spigroups.com

Dave Gentry
RedChipCompanies, Inc.
Phone:(407) 491-4498
dave@redchip.com

SOURCE: SPI Energy Co., Ltd

ReleaseID: 618095

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Commerce Resources Corp. (TSXV:CCE)(FSE:D7H0) (the "Company" or "Commerce") is pleased to announce that it has initiated a metallurgical program to produce a high-grade rare earth element (REE) mineral concentrate to satisfy a processor's request. The mineral concentrate will be produced from the Ashram Rare Earth and Fluorspar Deposit using the conventional recovery flowsheet developed at Hazen Research in CO, USA.

The Ashram Deposit's flowsheet has undergone significant development, including front-end piloting of the grinding, flotation, and leach circuits. The production of the requested mineral concentrate sample is expected to utilize the leach residue that was generated from this piloting completed in late 2015. The leach residue will be processed through the final magnetic separation stage to obtain the desired mineral concentrate grade (i.e. a high-grade monazite mineral concentrate). Following the production of this sample, the Company intends to continue to produce mineral concentrate for downstream processing, including piloting, to various mixed and partially separated rare earth products to satisfy other third-party sample requests.

The Ashram Deposit is one of only a select group of deposits in development globally that can produce mineral concentrate at high recovery (>70%) and high grade (>40% REO). All of the major hard rock REE miners globally produce mineral concentrates of at least 40% REO, which are then used for downstream processing to marketable products. Such high grades of mineral concentrate considerably reduce the downstream processing cost and risk through lower reagent use, fewer deleterious elements entering solution, and a smaller hydromet plant requirement by comparison.

The Company has successfully produced mineral concentrates from the Ashram Deposit exceeding 46% REO at >70% recovery using a conventional flowsheet approach of flotation, leaching, and magnetic separation. The third-party request to receive such a sample from Ashram is significant for several reasons.

Firstly, it is uncommon for mineral concentrates to be marketable outside of China, as the base saleable product is typically a downstream mixed rare earth carbonate or similar, which is the base feedstock to most REE separation facilities globally. Secondly, if successful and the Company is able to directly market a mineral concentrate without the need for a downstream hydromet facility in place, this would allow for a quicker path to production at significantly lower CAPEX and reduced technical risk. Further, it would allow for the downstream high-value product suite envisioned by the Company, which requires a hydrometallurgical facility, to be partially funded with cash flow from mineral concentrate production. As the Ashram Deposit is open-pittable and one of the largest rare earth deposits in the world, it has significant flexibility in production capacity and ability to service both upstream and downstream rare earth product suites.

As an additional benefit, the Company will also produce a fluorspar concentrate as the tailings to the REE recovery circuit. This will allow for further testwork to upgrade the fluorspar concentrate, expected to initially grade ~80% CaF2 in the tailings product, to acid-spar. By producing a tailings product of value, the Company is also helping to do its part in advancing the circular economy, specifically in Quebec, where a significant amount of fluorspar is consumed in the aluminum industry, among others.

NI 43-101 Disclosure

Darren L. Smith, M.Sc., P.Geo., Dahrouge Geological Consulting Ltd., a Permit holder with the Ordre des Géologues du Québec and Qualified Person as defined by National Instrument 43-101, supervised the preparation of the technical information in this news release.

About Commerce Resources Corp.

Commerce Resources Corp. is an exploration and development company with a particular focus on deposits of rare metals and rare earth elements. The Company is focused on the development of its Ashram Rare Earth Element Deposit in Quebec and the Upper Fir Tantalum-Niobium Deposit in British Columbia.

For more information, please visit the corporate website at www.commerceresources.com or email info@commerceresources.com.

On Behalf of the Board of Directors
COMMERCE RESOURCES CORP.

"Chris Grove"
Chris Grove
President and Director
Tel: 604.484.2700
Email: cgrove@commerceresources.com
Web: http://www.commerceresources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release contains forward-looking information which is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ from those projected in the forward-looking statements. Forward looking statements in this press release include that mineral concentrate will be produced from the Ashram using the conventional recovery flowsheet; is expected to utilize the leach residue from 2015; that following the production of this sample, the Company intends to continue to produce mineral concentrate for downstream processing; and that the Company will do further testwork to upgrade the fluorspar concentrate. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Risks that could change or prevent these statements from coming to fruition include that the methods proposed don't work as well as expected, the leach residue may not be usable, we may experience difficulties producing concentrate or achieving an upgrade to the concentrate; changing costs for mining and processing; increased capital costs; the timing and content of upcoming work programs; geological interpretations based on drilling that may change with more detailed information; potential process methods and mineral recoveries assumption based on limited test work and by comparison to what are considered analogous deposits that with further test work may not be comparable; testing of our process may not prove successful and even it tests are successful, the economic and other outcomes may not be as expected; the availability of labour, equipment and markets for the products produced; and despite the current expected viability of the project, conditions changing such that the minerals on our property cannot be economically mined, or that the required permits to build and operate the envisaged mine can be obtained. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

SOURCE: Commerce Resources Corp.

ReleaseID: 618056

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Grande West Transportation Group Inc. (TSX.V:BUS) (OTCQX:GWTNF) (FRA:6LG) – November 24, 2020: ("Grande West" or the "Company"), a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States, is pleased to announce the Vicinity LightningTM Electric Vehicle ("EV") specifications and is now for sale in Canada and the United States.

The Vicinity LightningTM EV, the first electric bus for Grande West, is the newest model in the Grande West portfolio and is officially being introduced to the world (See product presentation here https://vicinitybus.com/models/vicinity-lightning-ev/). The premiere of the vehicle is a landmark for Grande West and for the industry in the transitioning towards zero-emission transport. The Vicinity LightningTM will be an environmentally friendly alternative for diesel vehicles currently used in this segment.

The Vicinity LightningTM was designed from the ground up to be a cost effective, user friendly vehicle. The design will allow it to fit into any standard transit garage with no major infrastructural electrical upgrades. Grande West has partnered with world class industry leaders to engineer this highly advanced vehicle. Time and forethought were given to the design and engineering process with the customer in mind and the result is the industry-changing Vicinity LightningTM bus. The Company's sales team has started the process of introducing the product to prospective clients in the United States and Canada.

We are pleased to invite interested listeners to the presentation to be given by our Chief Operating Officer, Jonathan Leskewich. Following our financial and corporate update on the conference call today, a question and answer period will include the Vicinity LightningTM.

The conference call begins today at 11:00 AM EST. The call-in number is (877) 407-0782 or (201) 689-8567 (international), the webcast can be accessed at https://www.webcaster4.com/Webcast/Page/2233/38806 . A replay of the call will be available for 30 days at the webcast link or by calling (877) 481-4010 and entering PIN# 38806.

About Grande West Transportation Group

Grande West Transportation is a Canadian company that designs and engineers mid-size multi-purpose transit vehicles for public and commercial enterprises. Grande West utilizes world-class manufacturing partners to produce the Purpose-Built Vicinity heavy-duty bus available in clean diesel, gas, and CNG drive systems. The Vicinity LT EV with an electric propulsion drive system is available for 2021 deliveries.

The Company has been successful in supplying Canadian municipal transportation agencies and private operators with new buses. Grande West is compliant to Buy America certification, and with a strong distribution chain in the U.S., is actively pursuing opportunities in public and private transit fleet operations that would benefit from Grande West's vehicles.
www.grandewest.com

For investor relations, please contact:

Paradox Public Relations Inc.
Karl Mansour
Managing Director
Ph: (514) 341-0408 or 1-866-460-0408
IR@grandewest.com

Company contact:

Grande West Transportation
John LaGourgue
VP Corporate Development
Ph: 604-288-8043
IR@grandewest.com

Neither the TSX-V nor its Regulation Service Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, including without limitation, statements regarding the use of proceeds from the Private Placement, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," and similar expressions, or statements that events, conditions, or results "will," "may," "could," or "should" occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause actual results to differ materially from Grande West's expectations include uncertainties relating to the receipt of final approval from the TSX-V; and other risk and uncertainties disclosed in Grande West's reports and documents filed with applicable securities regulatory authorities from time to time. Grande West's forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. Grande West assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: Grande West Transportation Group Inc.

ReleaseID: 618069

Unaudited Results for the six months ended 30 September 2020

Corporate and Operational Update

TORONTO, ON / ACCESSWIRE / November 24, 2020 / Eco (Atlantic) Oil & Gas Ltd. (AIM:ECO)(TSX‐V:EOG), the oil and gas exploration company with licence interests in Guyana and Namibia, is pleased to announce its results for the three and six months ended 30 September 2020, alongside a corporate and operational update.

Results Highlights:

Financials

As at 30 September 2020, the Company had cash and cash equivalents of US$17.2 million with zero debt.
Eco remains fully funded for its share (15% WI net) of its planned two exploration wells at Orinduik Block offshore Guyana.
As at 30 September 2020, Eco had total assets of US$18.4 million, total liabilities of US$470,661 and total equity of US$18 million.
70% reduction in general and administrative expenses as compared to same six month period in 2019, including travel costs reduction of 82% and office cost reductions of 90% in line with previously reported COVID-19 cost discipline measures.

Operations

Multiple light sweet oil drilling prospects on the Orinduik block are currently being reviewed by the Company's and its licence partners (the "JV Partners"), with high-graded candidates being considered for the next drilling programme. The intention is to provide further definition to the Cretaceous interpretation and target selection for drilling.
On 30 June 2020, the Company and its JV Partners approved a budget in the amount of approximately US$5 million through to 31 December 2020 for 3D reprocessing based on new regional results and high grading of target selection. The Company's share of this budget is US$750,000.
The Company, together with its strategic alliance partners Africa Oil Corp., is currently reviewing and evaluating additional assets opportunities in both Africa and South America.

Outlook:

Guyana

Guyana continues to be one of the most prolific exploration regions in the world, with over nine billion barrels of oil discovered in the last five years. Eco and its JV Partners have already delivered two substantial oil discoveries on the Orinduik Block and the licence continues to offer significant upside potential.
As previously reported, Eco is fully funded for further drilling on the block and, with its JV Partners, is assessing all opportunities available to drill at least two exploration wells into the light oil cretaceous targets as soon as practical. The Company is fully aligned with its JV partners on careful target selection based on the reprocessed 3D for the next drilling campaign and Eco expects to be able to update the market on its next drilling plans in due course.

The Orinduik JV partners are Eco Atlantic (15% working interest ("WI")), Tullow Guyana B.V. ("Tullow") (Operator, 60% WI) and Total E&P Guyana B.V. ("Total") (25% WI) in partnership with Qatar Petroleum (government approval is expected imminently).

Namibia

Eco continues to benefit from a strategically significant acreage position in-country and is progressing its various work programmes on its four blocks offshore Namibia. The Company has witnessed considerable interest from multiple IOCs in Namibia.
The Company continues to monitor upcoming drilling activity in the region, which should potentially see up to five exploration wells drilled on behalf of ExxonMobil, Total, Maurel & Prom, Shell and ReconAfrica in the next 12 months.

Corporate

Due to the ongoing COVID-19 pandemic, Eco continues to keep a strict control over costs throughout the business. This cost drive continues to generate material savings and has ensured that Eco remains well capitalised with a strong balance sheet.

Gil Holzman, President and Chief Executive Officer of Eco Atlantic, commented:

"The Company remains well placed to capitalise on its strategic acreage in both Guyana and Namibia; both prolific hydrocarbon provinces. With no debt and strong cash reserves, Eco remains fully funded for its further near-term drilling plans in Guyana and continues to evaluate additional value enhancing opportunities.

"In Guyana, arguably one the most attractive exploration and production regions in the world in the past five years, we are excited to recommence drilling activity in due course and we are aiming to define targets through reprocessing and we hope to have target selection in the next six months allowing us to begin drilling preparation in the second half of 2021.

"In Namibia, we have seen a ramp up in activity by other operators towards their respective drilling programmes and we expect any success here to considerably benefit Eco. Namibia continues to become ever more attractive to the major players in the industry, and we look forward to an exciting year of activity in 2021 in country and for Eco.

"Eco's resilient business model, along with its strong management, shareholders, and assets in prolific E&P hotpots, means the Company is well positioned to deliver value for shareholders going forward. We very much look forward to keeping the market up to speed on developments for the remainder of 2020 and into the New Year."

The Company's unaudited financial results for three and six months ended 30 September 2020, together with Management's Discussion and Analysis for the three months and six months to 30 September 2020, are available to download on the Company's website at www.ecooilandgas.com and on Sedar at www.sedar.com.

The following are the Company's Balance Sheet, Income Statements, Cash Flow Statement and selected notes from the annual Financial Statements. All amounts are in US Dollars, unless otherwise stated.

Balance Sheet

 
September 30,
 
 
March 31,
 
 
April 1,
 

 
2020
 
 
2020
 
 
2019
 

Assets

 
Unaudited
 
 
Audited
 
 
Audited
 

Current assets

Cash and cash equivalents

 
 
17,192,996
 
 
 
18,667,016
 
 
 
18,750,453
 

Short-term investments

 
 
52,760
 
 
 
52,737
 
 
 
56,098
 

Government receivable

 
 
18,741
 
 
 
19,276
 
 
 
24,821
 

Amounts owing by licence partners, net

 
 
21,809
 
 
 
45,596
 
 
 
–
 

Accounts receivable and prepaid expenses

 
 
135,254
 
 
 
46,262
 
 
 
60,678
 

 
 
17,421,560
 
 
 
18,830,887
 
 
 
18,892,050
 

Petroleum and natural gas licences

 
 
1,117,171
 
 
 
1,117,171
 
 
 
1,117,171
 

Total Assets

 
 
18,538,731
 
 
 
19,948,058
 
 
 
20,009,221
 

Liabilities

Current liabilities

Accounts payable and accrued liabilities

 
 
131,192
 
 
 
350,242
 
 
 
317,548
 

Advances from and amounts owing to licence partners, net

 
 
339,469
 
 
 
–
 
 
 
845,524
 

Total Liabilities

 
 
470,661
 
 
 
350,242
 
 
 
1,163,072
 

Equity

Share capital

 
 
59,099,725
 
 
 
59,099,725
 
 
 
37,509,183
 

Restricted Share Units reserve

 
 
267,669
 
 
 
267,669
 
 
 
83,597
 

Warrants

 
 
53,026
 
 
 
53,026
 
 
 
39,570
 

Stock options

 
 
2,597,644
 
 
 
2,542,824
 
 
 
2,387,837
 

Foreign currency translation reserve

 
 
(1,205,801)
 
 
 
(1,117,859
)
 
 
–
 

Accumulated deficit

 
 
(42,744,193)
 
 
 
(41,247,569
)
 
 
(21,174,038
)

Total Equity

 
 
18,068,070
 
 
 
19,597,816
 
 
 
18,846,149
 

Total Liabilities and Equity

 
 
18,538,731
 
 
 
19,948,058
 
 
 
20,009,221
 

Income Statement

 
Three months ended
 
 
Six months ended
 

 
September 30,
 
 
September 30,
 
 
 
 

 
2020
 
 
2019
 
 
2020
 
 
2019
 

 
Unaudited
 
 
Unaudited
 

Revenue

Interest income

 
 
7,247
 
 
 
101,799
 
 
 
35,656
 
 
 
228,884
 

 
 
7,247
 
 
 
101,799
 
 
 
35,656
 
 
 
228,884
 

Operating expenses:

Compensation costs

 
 
141,322
 
 
 
259,487
 
 
 
313,626
 
 
 
420,527
 

Professional fees

 
 
87,799
 
 
 
219,355
 
 
 
120,414
 
 
 
236,119
 

Operating costs

 
 
330,738
 
 
 
5,189,188
 
 
 
850,415
 
 
 
11,368,546
 

General and administrative costs

 
 
142,267
 
 
 
358,545
 
 
 
229,270
 
 
 
752,831
 

Share-based compensation

 
 
42,177
 
 
 
5,611,560
 
 
 
54,820
 
 
 
5,619,111
 

Foreign exchange gain

 
 
(45,298)
 
 
 
220,535
 
 
 
(36,265)
 
 
 
181,965
 

Total expenses

 
 
699,005
 
 
 
11,858,671
 
 
 
1,532,280
 
 
 
18,579,099
 

Net loss and comprehensive loss

 
 
(691,758)
 
 
 
(11,756,872
)
 
 
(1,496,624)
 
 
 
(18,350,215
)

Basic and diluted net loss per share attributable to equity holders of the parent

 
 
(0.00)
 
 
 
(0.06
)
 
 
(0.01)
 
 
 
(0.10
)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share

 
 
184,697,723
 
 
 
182,038,204
 
 
 
184,697,723
 
 
 
181,112,949
 

Cash Flow Statement

 
Six months ended
 

 
September 30,
 

 
2020
 
 
2019
 

 
Unaudited
 

Cash flow from operating activities

Net loss from operations

 
 
(1,496,624)
 
 
 
(18,350,215
)

Items not affecting cash:

Share-based compensation

 
 
54,820
 
 
 
5,619,111
 

Warrants issued for services

 
 
 
 
 
 
–
 

Changes in non???cash working capital:

Government receivable

 
 
535
 
 
 
(7,154
)

Accounts payable and accrued liabilities

 
 
(219,050)
 
 
 
(207,303
)

Accounts receivable and prepaid expenses

 
 
(88,992)
 
 
 
23,014
 

Advance from and amounts owing to licence partners

 
 
339,469
 
 
 
903,619
 

 
 
(1,409,842)
 
 
 
(12,018,929
)

Cash flow from financing activities

Net proceeds from Private Placement

 
 
–
 
 
 
15,935,765
 

Proceeds from the exercise of stock options

 
 
–
 
 
 
53,971
 

Proceeds from the exercise of warrants

 
 
–
 
 
 
120,612
 

 
 
–
 
 
 
16,110,348
 

Increase (decrease) in cash and cash equivalents

 
 
(1,409,842)
 
 
 
4,091,419
 

Foreign exchange differences

 
 
(64,178)
 
 
 
305,733
 

Cash and cash equivalents, beginning of period

 
 
18,667,016
 
 
 
18,750,453
 

Cash and cash equivalents, end of period

 
 
17,192,996
 
 
 
23,147,605
 

Notes to the Financial Statements

Basis of Preparation

The condensed consolidated interim financial statements of the Company have been prepared on a historical cost basis with the exception of certain financial instruments that are measured at fair value. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

Summary of Significant Accounting Policies

Critical accounting estimates

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively from the period in which the estimates are revised. The following are the key estimate and assumption uncertainties considered by management.

Change in functional currency assessment

The functional currency of the Company and its subsidiaries represent the currency of the primary economic environment in which each entity operates. Through to March 31, 2020, all entities were considered to have a functional currency of Canadian Dollars. On March 31, 2020, the Company determined the United States Dollar ("USD") to be the functional currency for Eco Guyana based on the increased expenditures incurred in USD which is expected to continue in the foreseeable future. On April 1, 2020, the Company determined the USD to be the functional currency for Eco (Atlantic) Oil and Gas Ltd, based on the increase in USD denominated spending as of April 1, 2020. On April 1, 2020, the Company also determined the USD to be the functional currency of Eco Guyana Oil & Gas (Barbados) Ltd, since this entity is 100% owned by Eco Atlantic, and is the 100% owner of Eco Guyana, both of which have functional currencies denominated in USD. The change in estimate has been applied on a prospective basis effective April 1, 2020.

Effective April 1, 2020, the Company also changed its presentation currency from Canadian Dollars to USD. The change in presentation currency is to better reflect the Company's business activities and to improve investors' ability to compare the Company's results to its peers. This change has been applied retroactively as if the Company's new presentation currency has always been the Company's presentation currency.

**ENDS**

For more information, please visit www.ecooilandgas.com or contact the following:

Eco Atlantic Oil and Gas

c/o Celicourt +44 (0) 20 8434 2754

Gil Holzman, CEO

Colin Kinley, COO

Alice Carroll, Head of Marketing and IR

+44(0)781 729 5070 | +1 (416) 318 8272

Strand Hanson Limited (Financial & Nominated Adviser)

+44 (0) 20 7409 3494

James Harris

James Bellman

Berenberg (Broker)

+44 (0) 20 3207 7800

Matthew Armitt

Detlir Elezi

Celicourt (PR)

+44 (0) 20 8434 2754

Mark Antelme

Jimmy Lea

Hannam & Partners (Research Advisor)

Neil Passmore

+44 (0) 20 7905 8500

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

Notes to editors:

About Eco Atlantic:

Eco Atlantic is a TSX-V and AIM quoted Oil & Gas exploration and production Company with interests in Guyana and Namibia, where significant oil discoveries have been made.

The Group aims to deliver material value for its stakeholders through oil exploration, appraisal and development activities in stable emerging markets, in partnership with major oil companies, including Tullow, Total and Azinam.

In Guyana, Eco Guyana holds a 15% Working Interest alongside Total (25%) and Operator Tullow Oil (60%) in the 1,800 km2 Orinduik Block in the shallow water of the prospective Suriname-Guyana basin. The Orinduik Block is adjacent and updip to ExxonMobil Operated Stabroek Block, on which eighteen discoveries have been announced and over 9 Billion BOE of oil equivalent recoverable resources are estimated. First oil production commenced in December 2019 from the deep-water Liza Field, less than three years from FID.

Jethro-1 was the first major oil discovery on Orinduik Block. The Jethro-1 encountered 180.5 feet (55 meters) of net high-quality oil pay in excellent Lower Tertiary sandstone reservoirs which further proves recoverable oil resources. Joe-1 is the second discovery on the Orinduik Block and comprises high quality oil-bearing sandstone reservoir with a high porosity of Upper Tertiary age. The Joe-1 well encountered 52 feet (16 meters) of continuous thick sandstone which further proves the presence of recoverable oil resources.

In Namibia, the Company holds interests in four offshore petroleum licences totalling approximately 25,000km2 with over 2.3bboe of prospective P50 resources in the Walvis Basin. These four licences, Cooper, Guy, Sharon and Tamar are being developed alongside partners Azinam and NAMCOR. Eco has been granted a drilling permit on its Cooper Block (Operator).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Eco (Atlantic) Oil and Gas Ltd.

ReleaseID: 618174

ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 24, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology (SNO2020 Virtual Conference). Links to the Abstracts and Posters are provided below:

PNOC015: An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy (ABSTRACT DDRE-21) – Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro-Oncology Consortium

The Abstract may be found at: https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii66/5960703?redirectedFrom=fulltext

The Poster may be found at: http://midatechpharma.com/uploads/pdf/pnoc015.pdf

Efficacy of Soluble Panobinostat (MTX110) in Preclinical Models of Adult Glioblastoma (ABSTRACT TMOD-27) – Lead Author: Dr David Ashley, Preston Tisch Brain Tumor Centre, Duke University, Durham NC 27710

The Abstract may be found at: https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii233/5961404?redirectedFrom=fulltext

The Poster may be found at: http://midatechpharma.com/uploads/pdf/Conlon-TMOD27.pdf

Commenting, Steve Damment, EVP R&D of Midatech, said: "These presentations provide further information on the encouraging Phase I DIPG trial results recently announced by Midatech on 19 October 2020, and preclinical efficacy data supporting the potential utility of MTX110 for the significantly larger adult glioblastoma indication."

About MTX110
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).

For more information, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO

Steve Damment, EVP R&D

Tel: +44 (0)29 20480 180

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0)20 7886 2500

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker (Corporate Broking)

Tel: +44 (0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations)

Megan Paul

Tel: +1 (646) 653 7034

Email: mpaul@edisongroup.com

About Midatech Pharma PLC
Midatech Pharma PLC (dual-listed on LSE AIM:MTPH; and NASDAQ:MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

· Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

· MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

· MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

ReleaseID: 618087

DUBLIN, IRELAND / ACCESSWIRE / November 24, 2020 /

Key Highlights

Robust performance in a challenging trading environment
Further improvement in EBITDA and margin despite lower sales

Nine months ended 30 September

2020

LFL

Sales

$20.6bn

-3%

EBITDA

$3.4bn

2%

EBITDA Margin

16.60%

+100bps

Continued strong cash generation; expect year-end net debt/EBITDA of c. 1.4x
Non-cash impairment of c. $0.8bn expected in Q4
Agreement reached to divest of Brazil cement business for $0.2bn
Expect full-year EBITDA to be in excess of $4.4bn; ahead of 2019 on a LFL basis

Albert Manifold, Chief Executive, said today:

"As we continue to navigate these challenging times, the health and safety of our people remains our number one priority and is a core focus in our business each and every day. Markets continue to be impacted by the global pandemic and while we have seen some lower activity levels, I am pleased to report further improvement in trading performance, with an advance in both profitability and margins. The outlook for the coming months remains uncertain and visibility is limited, however, I am confident that we are well positioned for the challenges and opportunities that lie ahead."

Announced Tuesday, 24 November 2020

Health & Safety

As new waves of COVID-19 infections emerge across many of our markets, the health and safety of our people remains our number one priority. Our approach to workplace safety is uncompromising and our primary focus is to ensure that we provide a safe working environment for our employees, contractors and customers, enabling them to carry out their activities in accordance with the various health and safety protocols currently in place across our markets.

Trading Summary

Cumulative nine-month sales to the end of September amounted to $20.6 billion, a decrease of 3% compared with the corresponding period in 2019, maintaining the level of sales decline reported at the half year stage.

Third quarter trading in our Building Products Division was ahead, benefiting from strong residential repair, maintenance & improvement (RMI) demand in North America. While activity began to recover in Europe Materials in Q3, year-to-date sales remained behind prior year. In Americas Materials, Q3 sales performance was impacted by unfavourable weather conditions and a strong prior year comparative.

Sales (like-for-like1) change versus 2019

Americas Materials

Europe
Materials

Building
Products

Group

First half (H1)

-1%

-11%

+2%

-3%

Quarter 3 (Q3)

-7%

-2%

+4%

-3%

Nine months to September (9M)

-4%

-7%

+3%

-3%

Despite the lower sales, EBITDA for the period was $3.4 billion, up 1% on prior year and up 2% on a like-for-like basis reflecting a continued strong focus on cost rationalisation and mitigating actions to minimise the financial impacts of lower sales caused by the pandemic. The Group reported $65 million of non-recurring COVID-19 related restructuring items in the first six months of the year and we expect to incur similar costs in the second half.

EBITDA (like-for-like) change versus 2019

Americas
Materials

Europe
Materials

Building
Products

Group

First half (H1)

+20%

-28%

+11%

+2%

Quarter 3 (Q3)

+3%

+2%

+5%

+3%

Nine months to September (9M)

+9%

-14%

+9%

+2%

Trading Outlook

Based on the underlying trends in our businesses and recognising continued uncertainty across our markets, we expect full-year EBITDA to be in excess of $4.4 billion for 2020. For now, there is limited visibility into 2021, however the longer-term prospects for CRH remain positive, given our significant financial strength and operational resilience together with a portfolio of high-quality assets in attractive markets.

1 Like-for-like movements exclude the impact of currency exchange, acquisitions, divestments and non-recurring items.

Americas Materials

Nine-month like-for-like sales for our Americas Materials operations were 4% behind the equivalent period in 2019. Our North region was particularly impacted by COVID-19 restrictions earlier in the year while volumes in South were also impacted by delayed state lettings and unfavourable weather conditions. This was partly offset by healthy market fundamentals and solid backlogs in our West region along with pricing progress in most product lines. However, Q3 sales in the West region were impacted by unfavourable weather and wildfires in August and September. Our Cement business in North America experienced lower volumes in the first nine months of the year, however these were offset by pricing gains.

Like-for-like EBITDA for Q3 was ahead of 2019, resulting in nine-month EBITDA 9% ahead with solid price progression, good cost control and lower energy costs.

Key Products in Brief

Aggregates: Like-for-like aggregates volumes for the nine months were 3% behind 2019; average year-to-date prices increased by 3% with increases in all regions.
Asphalt: Delays in state lettings in the South region along with pandemic restrictions resulted in nine-month volumes 9% behind on a like-for-like basis; average prices were 2% behind impacted by lower bitumen input costs, however margins increased.
Readymixed Concrete: Volumes for the nine months were 5% behind 2019 on a like-for-like basis impacted by current year project delays along with the non-recurrence of large projects; average prices were 6% ahead.
Paving and Construction Services: Nine-month like-for-like sales in our paving and construction services business were 8% behind 2019 as solid activity in West was offset by pandemic restrictions and project delays in certain states.
Cement: COVID-19 restrictions, adverse weather conditions and lower demand from key sectors offset robust residential activity in western regions; nine-month like-for-like volumes were 1% behind 2019 while prices were 4% ahead with progress achieved in all markets.

Europe Materials

Nine-month like-for-like sales were 7% behind 2019, an improvement on the half year as trading activity recovered during Q3; however this was not sufficient to offset the impact of significant COVID-19 related government interventions and shutdowns in the second quarter. The United Kingdom (UK) which was one of the most significantly impacted markets saw some improvement in Q3 although activity levels are still below pre-COVID levels. Western European markets experienced improved activity levels in key markets as restrictions eased. Eastern European markets continued to trade well in Q3.

Like-for-like EBITDA for Q3 was ahead of prior year as improved pricing and the benefit of cost saving measures and lower energy costs offset the impact of lower volumes. Nine-month like-for-like EBITDA was 14% behind.

Key Markets in Brief

Western Europe: Despite some recovery in Q3 activity levels and continued pricing progress, nine-month sales were behind the prior year due to lower volumes which were impacted by strict COVID-19 restrictions in Q2, across a number of key markets such as the UK, Ireland and France. EBITDA was behind impacted by the lower sales, partly offset by cost rationalisation and improved cement pricing.
Eastern Europe: Nine-month sales were ahead of prior year as construction sites remained open throughout the pandemic. Higher cement volumes and improved pricing along with cost saving measures resulted in EBITDA ahead of the same period in 2019.
Asia: Despite record Q3 volumes, government shutdowns in the first half of the year resulted in lower nine-month volumes than prior year. Prices were also behind, impacted by product mix which resulted in lower sales compared to 2019. Lower energy costs along with operational and procurement initiatives resulted in EBITDA ahead for the nine months.

Building Products

Nine-month like-for-like sales were 3% ahead of 2019 reflecting strong volumes in Architectural Products, improved pricing in most platforms, benefits arising from commercial excellence, ongoing profit improvement and cost rationalisation initiatives. This resulted in strong operating leverage and like-for-like EBITDA for the nine months was 9% ahead of prior year.

Key Products in Brief

Architectural Products: Nine-month like-for-like sales and EBITDA were ahead of 2019 reflecting volume improvements in all key markets and product lines as well as selling price increases. In North America the significant increase in residential RMI demand experienced in the second quarter continued into Q3 while sales also remained robust in Europe, particularly in Germany and Poland. The businesses delivered strong operating leverage on the increased sales as price increases, disciplined cost control and the benefits of profit improvement initiatives were delivered.
Building Envelope: COVID-19 restrictions and "shelter in place" orders in key markets impacted volumes at both C.R. Laurence and our architectural glass operations, although the Q3 rate of decline softened with reduced restrictions. Nine-month like-for-like sales and EBITDA were behind 2019 as a result of lower volumes, partly offset by cost management initiatives to align costs with the lower activity levels.
Infrastructure Products: Nine-month like-for-like sales were behind prior year, driven by Q3 volume declines in North America due to slower demand in key product lines, COVID-19 restrictions in Europe earlier in the year and a downturn in the telecoms market in Australia. Despite the lower volumes, good pricing and stringent cost control resulted in nine-month like-for-like EBITDA ahead of 2019.
Construction Accessories: Nine-month like-for-like sales were behind the same period in 2019, mainly impacted by COVID-19 related business disruption in both Europe and North America. Some recovery has been experienced in recent months, particularly in Europe, while challenging market conditions continued to impact our businesses in North America. Like-for-like EBITDA was behind 2019, impacted by lower volumes and partly offset by cost reduction measures.

Profit Before Tax Outlook

We expect full-year depreciation and amortisation expense to be in line with last year (2019: $1.7 billion).

Arising from the Group's impairment testing process and as a result of the combined economic impacts of COVID-19 and Brexit, we expect to recognise non-cash impairment charges of c. $0.8 billion in our full-year results for 2020. These charges primarily relate to our UK business and our associate investment in China.

The net gain on divestments and non-current asset disposals in 2020 is expected to be c. $20 million (2019: $189 million loss).

The Group's share of profits from equity accounted entities (pre-impairment) is expected to be lower than prior year (2019: $67 million) mainly due to the divestment of the Indian joint venture along with the impact of COVID-19 restrictions on a number of operations.

Net finance costs are expected to be broadly in line with last year (2019: $490 million).

Taking each of these elements into account together with our EBITDA outlook, we expect full-year profit before tax (pre-impairment) to be ahead of 2019 (2019: $2.2 billion).

Balance Sheet Expectations

In line with our previous guidance, year-end net debt is expected to show a significant improvement on prior year (2019: $7.5 billion), to c. $6 billion resulting in net debt to EBITDA of approximately 1.4x based on robust EBITDA performance, continued strong working capital management, lower acquisition spend, lower capital expenditure in response to lower activity levels and a pause in the Group's share buyback programme.

Acquisitions and Divestments

The Group has spent c. $181 million on 14 acquisitions to date in 2020 (including deferred and contingent consideration in respect of prior year acquisitions).

On the divestment front, the Group completed seven transactions and realised total business and asset disposal proceeds of c. $263 million, inclusive of $122 million relating to the receipt of deferred proceeds from prior year divestments.

The agreement to divest our Brazil cement business for consideration of $0.2 billion is currently subject to competition authority review and the transaction is expected to close in 2021.

CRH will report its preliminary results for the full-year 2020 on Thursday, 4th March 2021.

CRH plc will host an analysts' conference call at 08:30 GMT on Tuesday, 24 November 2020 to discuss the Trading Update. To join this call please dial: +353 (0) 1 506 0650, confirmation code 1578116 (further international numbers are available here). A recording of the conference call will be available on the Results & Presentations page of the CRH website.

Contact CRH at +353 1 404 1000

Albert Manifold Chief ExecutiveSenan Murphy Finance Director

Frank Heisterkamp Director of Capital Markets & ESG

Tom Holmes Head of Investor Relations

About CRH

CRH (LSE:CRH)(ISE:CRG)(NYSE:CRH) is the leading building materials business in the world, employing c.79,000 people at c.3,100 operating locations in 30 countries. It is the largest building materials business in North America, a leading heavyside materials business in Europe and has positions in both Asia and South America. CRH manufactures and supplies a range of integrated building materials, products and innovative solutions which can be found throughout the built environment, from major public infrastructure projects to commercial buildings and residential structures. A Fortune 500 company, CRH is a constituent member of the FTSE 100 Index, the EURO STOXX 50 Index, the ISEQ 20 and the Dow Jones Sustainability Index (DJSI) Europe. CRH's American Depositary Shares are listed on the NYSE.

For more information visit www.crh.com

Disclaimer

In order to utilise the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, CRH public limited company (the "Company"), and its subsidiaries (collectively, "CRH" or the "Group") is providing the following cautionary statement.

This document contains statements that are or may be deemed to be forward-looking statements with respect to the financial condition, results of operations, business, viability and future performance of CRH and certain of the plans and objectives of CRH. These forward-looking statements may generally, but not always, be identified by the use of words such as "will", "anticipates", "should", "could", "would", "targets", "aims", "may", "continues", "expects", "is expected to", "estimates", "believes", "intends" or similar expressions. These forward-looking statements include all matters that are not historical facts or matters of fact at the date of this document.

By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future and reflect the Company's current expectations and assumptions as to such future events and circumstances that may not prove accurate.

A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, certain of which are beyond our control, as detailed in the section entitled "Risk Factors" in our 2019 Annual Report on Form 20-F as filed with the US Securities and Exchange Commission.

You are cautioned not to place undue reliance on any forward-looking statements. These forward-looking statements are made as of the date of this document. The Company expressly disclaims any obligation or undertaking to publicly update or revise these forward-looking statements other than as required by applicable law.

The forward-looking statements in this document do not constitute reports or statements published in compliance with any of Regulations 6 to 8 of the Transparency (Directive 2004/109/EC) Regulations 2007.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: CRH PLC

ReleaseID: 618085

VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Noram Ventures Inc. ("Noram") (TSXV:NRM)(Frankfurt:N7R)(OTCQB:NRVTF) is pleased to announce that the Company has continued drilling in mineralization at depth on Hole #7 (CVZ-62).

Figure 1 – LF-70 drill rig on CVZ-62 site, 2020-11-17, Brad Peek, Senior Geologist and Q.P. on site, looking northwest. CVZ-62 has 50 meters of lithium claystone and is continuing to drill in the claystones. Samples have been submitted to ALS laboratories for analysis.

The Zeus property Esmeralda Formation playa lake bed sediments are horizontal and laterally continuous strata over kilometers and each drill intersection has a large radius of influence for resource estimates. This is evident in the February 20, 2019, Updated Inferred Lithium Mineral Resource Estimate, Zeus Project, Clayton Valley, Esmeralda County, Nevada, USA NI 43-101 technical report for the Zeus property, where the radius of influence is 250 meters or greater. "The prior hole CVZ-61, intersected approximately 298ft (91m) of lithium claystone. With a specific gravity of 1.74 g/cc for the claystone material, this corresponds to ~31 million tonnes that potentially can be added to the resources from this one intersection alone" commented Anita Algie, Director and CFO.

"CVZ-61 is to the east of a NE-SW possible fault, and it appears that the fault has not affected the claystone unit in a measurable way; i.e., there is no measurable displacement along the fault. This bodes well for the rest of the drilling to the east of the fault, which will cover an area approximately the same as the current resources (at >900 ppm lithium cutoff)" stated Brad Peek, consulting geologist and Qualified Person for this and all 4 of the previous drilling phases of Noram's Zeus Lithium property.

President and CEO, Dr. Tucker Barrie visited the Project this past week and reported:

"The Fall drill program is proceeding well. At present we have an LF-70 drill rig that can produce 50-60 feet of core per 12 hour shift. We are running one shift a day at present, but we will soon be going to 2 shifts with a Longyear 44 rig that is capable of 120+ feet per shift. We are on track to complete the drill program before Christmas.

On this visit I had the opportunity to meet with our neighbors in Clayton Valley who are producers of lithium and of other resources. There is potential for synergies in the production of these resources moving forward, and we will continue to have discussions in this regard. "

As well, I met with senior geologists from the Nevada Bureau of Mines and the United States Geological Survey to update them of our activities and to hear about their research related to lithium claystone deposits in Nevada. There are many ways we can work together, including providing access to our property and drill core for detailed mineralogical studies, and working toward possible lithium symposia in Nevada in the future. It would be ideal to gather industry, academia and the geological surveys to discuss Nevada's significant lithium resources and how to increase production for the growing electric vehicle market. "

The technical information contained in this news release has been reviewed and approved by Brad Peek., M.Sc., CPG, who is a Qualified Person with respect to Noram's Clayton Valley Lithium Project as defined under National Instrument 43-101.

About Noram Ventures Inc.

Noram Ventures Inc. (TSX – Venture: NRM / Frankfurt: N7R / OTCQB: NRVTF) is a Canadian based junior exploration company, with a goal of developing lithium deposits and becoming a low – cost supplier. The Company's primary business focus since formation has been the exploration of mineral projects. Noram's long term strategy is to build a multi-national lithium minerals company to produce and sell lithium into the markets of Europe, North America and Asia.

Please visit our web site for further information: www.noramventures.com

ON BEHALF OF THE BOARD OF DIRECTORS
/s/ "Anita Algie."
Director and CFO
Office: (604) 553-2279

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward-looking information in this news release includes statements regarding, among other things, the completion transactions completed in the Agreement. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, regulatory approval processes. Although Noram believes that the assumptions used in preparing the forward-looking information in this news release are reasonable, including that all necessary regulatory approvals will be obtained in a timely manner, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Noram disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by applicable securities laws.

SOURCE: Noram Ventures Inc.

ReleaseID: 618026

EVOTEC TO SUPPORT RAPPTA IN DEVELOPING SMALL MOLECULES THAT REACTIVATE PP2A, A KEY TUMOR SUPPRESSOR
THE COLLABORATION LEVERAGES EVOTEC'S ONCOLOGY EXPERTISE AND INTEGRATED DRUG DISCOVERY AND DEVELOPMENT PLATFORM

HAMBURG, GERMANY / ACCESSWIRE / November 24, 2020 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a new multi-year drug development partnership with Rappta Therapeutics, a Finland-based biopharmaceutical company, focused on an innovative oncology target.

Under the partnership, Evotec will support Rappta's programme of developing small molecule activators of the enzyme Protein Phosphatase 2A ("PP2A"), which downregulates multiple oncogenic signalling pathways responsible for driving cancer progression. Although PP2A is a key tumour suppressor and has a critical function regulating protein de-phosphorylation and tumour growth, it has to-date been very difficult to target pharmaceutically.

Through its deep understanding of PP2A biology and the use of proprietary technology, Rappta has uniquely defined the PP2A target which has allowed them to come up with a series of first-in-class compounds which glue the three subunits of PP2A together, thus driving PP2A complex reformation and restoring its tumour suppressive function. Evotec and Rappta intend to develop the programme which is currently in the late lead optimisation stage towards IND-enabling studies over the course of their partnership.

The collaboration leverages Evotec's industry-leading integrated platform for drug discovery and development including Evotec's oncology expertise coupled with state-of-the-art technologies to maximise probability of success even in fields of cutting-edge and difficult science. Evotec receives undisclosed research funding and is eligible for success-based milestone payments.

Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "Evotec is pleased to initiate this first collaboration with Rappta Therapeutics supporting their novel and next generation platform targeting PP2A against cancer. Evotec has a long and successful track record in the oncology field, having achieved numerous milestones including multiple pre-clinical candidates and clinical-stage assets together with our partners. We have been thoroughly impressed with the progress that Rappta has made in mapping out the PP2A target and look forward to working with them to continue their success by delivering solutions for patients with unmet medical needs."

Mikko Mannerkoski, the CEO of Rappta Therapeutics, added: "We are excited to be working on building a new platform and a novel class of pharmaceuticals to treat cancer. Rappta has a unique team whose deep understanding of PP2A biochemistry, structural biology, biogenesis, medicinal chemistry, and drug development is further supported by Evotec's capabilities. This is the perfect combination of expertise to translate these discoveries to the clinic."

ABOUT PROTEIN PHOSPHATASE 2A
Reversible phosphorylation is a fundamental mechanism controlling all cell signaling and communication and this process is regulated through the opposing actions of phosphatases (which remove phosphate groups from proteins) and kinases (which add phosphate groups to proteins). Altered cellular signaling as a result of protein hyperphosphorylation, results in the sustained growth of malignant cells and is a hallmark of human cancer development and progression. Protein Phosphatase 2A (PP2A) is a serine/threonine phosphatase that functions as a tumor suppressor by negatively regulating multiple oncogenic signaling pathways responsible for driving cancer progression. PP2A is made up of three subunits, that form a complete and active enzyme when bound together. The active enzyme is comprised of a scaffolding subunit (A), serving as the structural platform for the assembly of the catalytic (C) subunit and one substrate directing regulatory (B) subunit. In cancer, the tumor-suppressive activity of PP2A is often disrupted as a result of the inability of the three subunits to bind together correctly, rendering the PP2A enzyme inactive. This inactivation of PP2A, leads to increased oncogenic signaling, driving cancer progression and growth. Therefore, the reactivation of PP2A affords a unique therapeutic strategy to restore PP2A activity and cellular homeostasis, that can be used for the treatment of cancer and a broad range of other diseases.

ABOUT RAPPTA THERAPEUTICS
Rappta Therapeutics, a private biotech with operations in Finland and the US, is developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A). It has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth, with the potential to create a new class of anti-cancer drugs. Rappta has a strong scientific, management and commercial team. Its scientific team represents world-leading expertise in PP2A. Rappta Therapeutics is backed by blue-chip investors Advent Life Sciences, Novartis Venture Fund, Novo Holdings and a family office. For more information, go to www.rappta-therapeutics.com.

ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

FORWARD-LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Media Contact Evotec SE:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

IR Contact Evotec SE:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

SOURCE: Evotec AG via EQS Newswire

ReleaseID: 618169

GENEVA, SWITZERLAND and RADNOR, PA / ACCESSWIRE / November 24, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company") and NeuroRx, Inc., announced that more than 175 patients with Critical COVID-19 and Respiratory Failure who also have a severe comorbidity have now been entered into an Expanded Access Protocol (EAP) with RLF-100(TM) in the United States.

All patients had severe comorbidities (such as organ transplant, recent heart attack, and cancer) that rendered them ineligible for the ongoing randomized, controlled phase 2b/3 trial being conducted to ascertain safety and efficacy of RLF-100(TM), and all patients were deteriorating despite treatment with approved therapies for COVID-19 (see www.clinicaltrials.gov NCT 04311697). Of the 90 patients who have so far reached 28 days of follow-up, 72% survived to day 28.

As previously reported by Youssef and coworkers (http://dx.doi.org/10.2139/ssrn.3665228), at Houston Methodist Hospital, 21 patients treated with RLF-100(TM) under the EAP were compared to 24 control patients treated in the same setting. Only 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28. The survival rate with RLF-100(TM) reported today is comparable to that seen among the open-label patients treated with RLF-100(TM) by Youssef et al. Despite advancements in treating COVID-19, survival for the patients at highest risk due to severe comorbidities has remained dismal in the absence of an effective therapy.

Notably, in the EAP, no drug-related Serious Adverse Events have been reported to date among these patients nor the 160 patients randomized to RLF-100(TM) vs. placebo in the U.S. phase 2b/3 clinical trial currently underway. Thus, from a risk/benefit perspective, while the benefit of RLF-100(TM) has not yet been proven in a randomized prospective trial, no serious risk has been identified so far.

Currently, 25 U.S. hospitals have enrolled patients in the EAP, nearly all of which are community hospitals, suggesting that RLF-100(TM) can demonstrate effectiveness in the hands of front-line physicians who deliver the majority of care to patients with Critical COVID-19. Physicians enrolling patients in the EAP have routinely reported that initial patients at their sites have frequently been in the ICU for several weeks without recovery prior to treatment with RLF-100(TM). As patients are treated earlier in the course of their ICU stay, there is an emerging clinical impression that RLF-100(TM) has an even greater impact on recovery.

"We are reassured that emerging real-world data on the use of RLF-100(TM) in improving survival in patients with Critical COVID-19 are comparable to results seen in the hands of major academic teaching centers. We hope that these findings are viewed as encouraging at a time when many Americans, including the doctors, nurses, and other front-line caregivers who are the heart of our initiative, are celebrating the Thanksgiving holiday at a distance from their loved ones. We look forward to completing enrollment and reporting the results of our pivotal U.S. clinical trial," said Prof. Jonathan C. Javitt, MD, MPH, CEO and founder of NeuroRx, Inc.

ABOUT VIP IN LUNG INJURY
Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the alveolar type 2 cell, that is critical to transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.

Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and are essential for oxygen exchange. Other than RLF-100(TM), no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.

ABOUT RLF-100(TM)
RLF-100(TM) (Aviptadil) is a formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Sami Said's original work at Stony Brook University, for which Stony Brook was awarded an FDA Orphan Drug Designation in 2001. VIP is known to be highly concentrated in the lungs, where it inhibits coronavirus replication, blocks the formation of inflammatory cytokines, prevents cell death, and upregulates the production of surfactant. FDA has now granted IND authorization for intravenous and inhaled delivery of RLF-100(TM) for the treatment of COVID-19 and awarded Fast Track designation. RLF-100(TM) is being investigated in two placebo-controlled US Phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Since July 2020, more than 150 patients with Critical COVID-19 and Respiratory Failure have been treated with RLF-100(TM) under FDA-approved protocols. Information on the RLF-100(TM) Expanded Access program is at https://www.neurorxpharma.com/our-services/rlf-100.

ABOUT RELIEF THERAPEUTICS HOLDING AG
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the U.S. and multiple other countries covering potential formulations of RLF-100(TM).

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on the OTCQB under the symbol RLFTF.

ABOUT NEURORX INC.
NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100(TM), NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for RLF-100(TM) for the treatment of COVID-19. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACT
RELIEF THERAPEUTICS Holding AG
Raghuram (Ram) Selvaraju, Ph.D., MBA
Chairman of the Board
Mail: contact@relieftherapeutics.com
www.relieftherapeutics.com

NeuroRx, Inc.
Jonathan C. Javitt, M.D., MPH
Chairman and Chief Executive Officer
Mail: ceo@neurorxpharma.com

MEDIA CONTACT:
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
David Schull
Russo Partners, LLC
Tel.: +1 (0) 858-717-2310
Mail: david.schull@russopartnersllc.com

INVESTOR RELATIONS
Relief (Europe)
MC Services AG
Anne Hennecke / Brittney Sojeva
Tel.: +49 (0) 211-529-252-14
Mail: relief@mc-services.eu

NeuroRx (United States)
Brian Korb
Solebury Trout
Tel.: +1 (0) 917-653-5122
Mail: bkorb@troutgroup.com

SOURCE: Relief Therapeutics Holdings AG via EQS Newswire

ReleaseID: 618165

BETHESDA, MD / ACCESSWIRE / November 23, 2020 / HF Enterprises Inc. (NASDAQ:HFEN)(the "Company"), a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities, today announced the pricing of its initial public offering of 2,160,000 shares of its common stock at a public offering price of $7.00 per share for gross proceeds of $15,120,000 before deducting offering expenses. In addition, the Company has granted Aegis Capital Corp. a 60-day option to purchase up to 15% of additional shares of common stock at the public offering price to cover over-allotments, if any. The shares are expected to begin trading on The Nasdaq Capital Market on November 24, 2020, under the symbol "HFEN."

Aegis Capital Corp. is acting as lead bookrunning manager.

WestPark Capital, Inc. is acting as co-manager.

A registration statement relating to the shares of common stock being sold in this offering was declared effective by the Securities and Exchange Commission (the "SEC") on November 12, 2020. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC's website, www.sec.gov, or by contacting Aegis Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at syndicate@aegiscap.com, or by telephone at (212) 813-1010.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About HF Enterprises Inc.

HF Enterprises Inc. is a diversified holding company principally engaged through its subsidiaries in property development, digital transformation technology and biohealth activities with operations in the United States, Singapore, Hong Kong, Australia and South Korea. The Company manages its three principal businesses primarily through its subsidiary, Alset International Limited (formerly known as "Singapore eDevelopment Limited"), a public company traded on the Singapore Stock Exchange. Through this subsidiary (and indirectly, through other public and private U.S. and Asian subsidiaries), the Company is actively developing two significant real estate projects near Houston, Texas and in Frederick, Maryland in the property development segment. The Company has designed applications for enterprise messaging and e-commerce software platforms in the United States and Asia in the digital transformation technology business unit. The Company's recent foray into the biohealth segment primarily includes research to treat neurological and immune-related diseases, nutritional chemistry to create a natural sugar alternative, research regarding innovative products to slow the spread of disease, and certain natural foods and supplements.

Investor Contact:

Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
Dave@redchip.com

Forward-Looking Statement Disclaimer

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, including the Company's expectations regarding the proposed offering of the Company's shares of common stock, including as to the consummation of the offering described above and the size of the offering are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: HF Enterprises Inc.

ReleaseID: 618131